---
schema_version: "secwatch.filing_event.v1"
accession: "0001628280-26-034583"
form_type: "8-K"
ticker: "ALLO"
cik: "0001737287"
company_name: "Allogene Therapeutics, Inc."
filed_at: "2026-05-13T20:03:30+00:00"
generated_at: "2026-05-13T22:17:59.887965+00:00"
event_type: "earnings"
sentiment: "neutral"
materiality_score: 0.65
calibrated_materiality_score: 0.65
confidence: "high"
source: SEC EDGAR
---

# Allogene Q1 net loss $42.6M; ALPHA3 interim shows 58% MRD clearance; cash runway extended to Q1 2029

## Summary
- Terminated exclusive license with Overland; retains ~3% equity; no termination payments.
- ALPHA3 interim: 58.3% MRD clearance in cema-cel arm vs 16.7% observation; no CRS/ICANS/GvHD.
- Q1 net loss $42.6M ($0.18/sh); operating cash expense guidance raised to ~$165M.
- Cash $266.9M; April public offering grossed $200.4M; runway into Q1 2029.
- ALLO-329 Phase 1 RESOLUTION dosed 9 patients; initial signs of activity; next update Q4 2026.

## SEC filing metadata
- accession: 0001628280-26-034583
- form_type: 8-K
- ticker: ALLO
- cik: 0001737287
- company_name: Allogene Therapeutics, Inc.
- filed_at: 2026-05-13T20:03:30+00:00
- event_type: earnings
- sentiment: neutral
- materiality_score: 0.65
- calibrated_materiality_score: 0.65
- confidence: high
- sec_items: 1.01, 1.02, 2.02, 9.01
- EDGAR index: https://www.sec.gov/Archives/edgar/data/1737287/000162828026034583/0001628280-26-034583-index.htm
- EDGAR primary document: https://www.sec.gov/Archives/edgar/data/1737287/000162828026034583/allo-20260512.htm

## Machine-readable alternates
- HTML: https://secwatch.observer/filing/0001628280-26-034583
- JSON: https://secwatch.observer/filing/0001628280-26-034583.json
- Plain text: https://secwatch.observer/filing/0001628280-26-034583.txt

This AI-assisted summary is a reading aid. Review the linked SEC EDGAR filing before relying on any specific claim.